Alnylam Pharmaceuticals, Inc.

• 3 Small Biotechs Top Hedge Funds Are Investing In

  By Shas Dey - April 23, 2013 | Tickers: ACOR, ALNY, IDIX

  Small biotech companies have great investment potential if you can identify them properly. A small biotech with a differentiated treatment approach and strong commercialization plans can become a rainmaker. However, given the level of cutting edge technology they use, a layperson without an MD or an advanced degree in statistics can hardly get a grip on these companies and what they are all about. Unless you know just how good more »

• Is RNA Drug Development Coming of Age?

  By Terry Chrisomalis - April 11, 2013 | Tickers: ALNY, ISIS, SRPT

  Of late, it seems that good things are happening with RNA drug companies. There are a few biotech stocks that are advancing their pipelines in the RNA field, and breakthroughs in RNA will lead to a huge boost for these drug companies. On Oct. 2, 2006, Dr. Craig Mello and his colleague Andrew Fire were awarded the Nobel Prize for their discovery of RNA interference. 

  It has been a long more »

• Is RNA Drug Development Coming Of Age?

  By Terry Chrisomalis - April 8, 2013 | Tickers: ALNY, ISIS, SRPT

  Lately it seems good things are happening with RNA drug companies. There are a few biotech stocks that are advancing their pipelines in the RNA field, and breakthroughs in RNA will lead to a huge boost for these drug companies. On October 2, 2006 Dr. Craig Mello, and his colleague Andrew Fire were awarded the Nobel Prize for their discovery of RNA interference. 

  It has been a long road for more »

• Opko's Massive Insider Buys: Should Investors Follow Suit?

  By Alex Bastardas - March 7, 2013 | Tickers: ALNY, MRK, OPK

  "There are many reasons for an insider to sell a stock, but only one to buy it: he expects to make money." So goes the saying. Many investors invest their time in tracking insider transactions, as it is assumed that a company insider probably has some unique insights into the company's business, and likely expects those shares to go up in the future. If that's true, then Dr more »

• Three Stocks For The Long Haul

  By Declan Fallon - March 6, 2013 | Tickers: ATVI, ALNY, ISIS, NTES, THC

  I have reviewed over 80 stocks as investment opportunities. Some were more successful than others; for example, Tesoro Corporation (best performer) gained 99% within a sector that has underperformed the broader market, but Penn Virginia Corp (worst performer) dropped 33% and is unlikely to recover from the share dilution that cut the price. Collectively, 65% of the stocks I have featured have gained, with an average return of 6.6 more »

• Prognosis Positive: Medical Growth Stocks to Watch

  By Matt Swayne - January 29, 2013 | Tickers: ALNY, CELG, EBS, EXEL

  Skyrocketing healthcare costs will not be solved by politicians. Why do I say this? Because, let me ask you, when have politicians solved anything?
  
  Go ahead. Take your time. I’ll wait.
  
  Politicians may struggle to tame medical costs, but medical research firms are new treatments for many of the world’s most devastating -- and costly -- diseases. This can lead to new less expensive cures and a healthier and more more »

• Insider Alert: Should we Buy as Well?

  By Brian Gorban - March 1, 2012 | Tickers: ALNY, AN, KRO, OPK

  Insider buying is always a strong indicator that a stock is poised to move higher since insiders buy for only one reason: to make more money. Moreover, they arguably have the best view of where a stock is headed being a part of the day-to-day operations and/or having a large sum of money at stake. Below are some stocks recently with sizeable insider buying and my take on whether more »

• Alnylam Riding High on RNAi Drug Delivery News

  By Amanda Alix - January 30, 2012 | Tickers: ALNY, MRK, PFE, RHHBY

   Cambridge-based Alnylam Pharmaceuticals (NASDAQ: ALNY) is staging a comeback as the U.S. Patent and Trademark Office (USPTO) issued the company a Notice of Allowance on its lipid nanoparticle (NLP) delivery system for its RNA interference drugs.  This is excellent news for biotech in general, but especially for Alnylam, which has seen its stock drop like a stone in recent months as the larger players in the drug industry have more »

• Jim Cramer Watch: Tracking 5 'Mad Money' Picks

  By Robert Fisher - January 23, 2012 | Tickers: ALLT, ALNY, COG, JBHT, SD

  Stock market specialist Jim Cramer recommended that you buy these five stocks recently on his January 3rd episodes of Mad Money.  In this article, I analyze his picks on a relative value basis and analyze each stock's performance since Cramer's recommendation. 

  Allot Communications (NASDAQ: ALLT): Jim Cramer recommended this stock about a month ago when it was at $15.82 per share after climbing over $17 per share more »